



HAUTE AUTORITÉ DE SANTÉ

# Organization of the French Technical Vaccination Committee

---

Dr Agathe Billette de Villemeur

**Prevention and control of HPV and HPV related cancers in France: the  
current landscape and way forward**

2-3 December, 2021

**VEYRIER-DU-LAC, ANNECY, FRANCE**

# HAS : National Health Authority

- **Evaluating Health Products and Technologies**
  - **Drug and Medical Device Evaluation**
  - Procedure and Intervention Evaluation
  - **Health Economic Evaluation**
- **Recommending Best Practices**
  - Best Practice Guidelines
  - Public Health Guidelines
  - **Vaccine Guidelines**
  - Health Pathways and Relevant Care
  - Tools and Patient Safety Programs
  - Accreditation of Computerized Physician Order Entry (CPOE)
- **Measuring and Improving**
  - Accreditation of Hospitals and Clinics
  - Evaluation of Social Care Services and Facilities
  - Quality and Safety Indicators of Care
  - Physician and Medical Team Accreditation for High-Risk Practices
  - Public Information and Quality of Care Management

# Governance

**President  
Pr Dominique le Guludec**

**General Director  
Thomas Wanecq**

**Directeur délégué**

**General Secretariat**

**Medical, Economic and Public Health  
Assessment Department**

**Improvement in Quality Care and Safety  
Department**

**Quality of Social Care Department**

**Communication, Information and Public  
Involvement Department**

**Board**

**Transparency Committee**

**Economic and Public Health Committee**

**Medical Technology and Interventional  
Procedure Committee**

**Vaccine Committee**

**Healthcare Organisation Accreditation  
Committee**

**Guideline Impact Committee**

**Social Services Committee**

**Health Care Management Committee**

# Governance

**President  
Pr Dominique le Guludec**

General Director  
Thomas Wanecq

Directeur délégué

**Board**

Transparency Committee

Economic and Public Health Committee

Evaluate vaccines with Marketing Authorisation;  
Provide recommendations for vaccines with respects to reimbursement by the National Health Insurance Fund;  
Publish relevant and independent scientific information on vaccines;

Quality of Social Care Department

Communication, Information and Public Involvement Department

Guideline Impact Committee

Social Services Committee

Health Care Management Committee

# Governance

**President  
Pr Dominique le Guludec**

General Director  
Thomas Wanecq

Directeur délégué

**Board**

Transparency Committee

Economic and Public Health Committee

Give public health recommendations and technology appraisals based on clinical and economic evidence;  
Review technology assessments from manufacturers and issues opinions on their efficiency;  
Give an economic opinion on vaccines.

Quality of Social Care Department

Communication, Information and Public Involvement Department

Guideline Impact Committee

Social Services Committee

Health Care Management Committee

# Governance

**President  
Pr Dominique le Guludec**

General Director  
Thomas Wanecq

Directeur délégué

General Secretariat

Medical, Economic and Public Health  
Assessment Department

Improvement in Quality Care and Safety  
Department

Quality of Social Care Department

Communication, Information and Public  
Involvement Department

**Board**

Transparency Committee

Economic and Public Health Committee

Medical Technology and Interventional  
Procedure Committee

Vaccine Committee

Healthcare Organisation Accreditation  
Committee

Guideline Impact Committee

Social Services Committee

Health Care Management Committee

# Before being moved to the HAS, the CTV was a commission of the HCSP



**High Council for Public Health in France**

**National Health Authority**

**CTV**



**CTV**

**From 1997 to 2017**

**From 2017**

**Coordination its work with that of the Transparency Committee and the Economic and Public Health Committee**

# Technical Vaccination Committee (CTV)

**Vaccination policy** is developed by the **Ministry of Health** after receiving the opinion of the National Health Authority (HAS).

The CTV is tasked with preparing the HAS' Board deliberations:

- *Vaccine recommendations, including urgent Ministry of Health requests, or request from patients, or professionals' associations, or pharmaceutical company submission :*
  - *with epidemiological data,*
  - *studies on the benefits and risks of vaccination,*
  - *the absence of vaccination at the individual and collective levels,*
  - *and medico-economic studies*
- *Immunisation schedule*
- *Mandatory vaccinations*
- *Minimal disclosures required in publicity campaigns for vaccines*

# Technical Vaccination Committee (CTV)

## ➤ Composition

- 28 members with voting rights
  - ▶ 1 President, appointed by the President of the board from among the members of the board ;
  - ▶ 3 Vice-Presidents: the President of the transparency committee, the President of the Economic and Public Health Committee, one Vice-President appointed by decision of the board from among the 25 members below.
  - ▶ 25 members appointed by decision of the College for a period of three years, renewable twice
    - ▶ 23 members in the fields of paediatric medicine, general practice, infectiology, vaccinology, biology, methodology and epidemiology, health economics, public health, occupational medicine, gerontology, microbiology, and immunology ;
    - ▶ 2 members chosen from among the members of an association of patients and users of the health system.
- 9 institutional members with consultative vote
- **Selection of CTV members with strict rules for preventing links of interest (Health Transparency Database) in a context of strong**

# Method

## ➤ **The CTV's bureau :**

- decides on the procedure for the appraisal after examining the questions and organises the modalities of response
- defines the composition of the working group

## ➤ **Participation:**

- Working group (CTV members, experts of the HAS, interviews, ..)
- Economic and Public Health Committee

## ➤ **Public comment** if no emergency after publication of the draft

## ➤ **Investigation procedure**

- **Emergency** situation
  - e.g. Covid vaccine
- **AVIVAC = no change of strategy**
  - e.g. influenza vaccine with three (trivalent) or four (quadrivalent) valences
- **RECOVAC = new strategy**
  - New vaccine
  - Evolution of strategy
  - e.g. HPV

# Example: HPV recommendations and advices

Years			
03/2007	Screening cancer & Gardasil : girls 14 years & women 15-23 yers	04/2007	CT: Gardasil ASMR=3
12/2007	Cervarix < Gardasil	03/2008	CT Cervarix
12/2010	Cervarix = Gardasil		
10/2011	Young women Gardasil ? Young girls and women 14-23 years	02/2012	CT Gardasil
09/2012	HPV vaccine: girls 11-14 years & women <20 years	03/2013	CT: Cervarix & Gardasil ; 65% reimbursement by National Health Insurance Fund
02/2014	Cervarix: 2 doses if 11-14 years		
03/2014	Gardasil 2 doses if 11-13 years		
02/2016	Men CEGID (HIV screening)		
02/2017	Gardasil 9: girls 11-14 ans; women <20 years	09/2017	CT: Gardasil 9 economic evaluation
12/2019 & 3/2020			Men Gardasil 9 CT: reimbursement; ASMR = 3

# Example: HPV recommendations

## Gardasil 2007 (HCSP then HAS CT)

### ➤ **HCSP : analysis**

- ✓ Cervical cancer incidence
- ✓ HPV: etiology of precancerous lesions and cancer 15-25 years after infection
- ✓ Gardasil vaccine efficacy against infection = 95% (MSD)
- ✓ Undesirable effect= not severe
- ✓ Age of sexual intercourse: 3% before 15 years
- ✓ Cervical cancer screening by cervical smear; risk of lower screening

### ➤ **HCSP: Recommendation:**

- ✓ Emphasize the value of screening
- ✓ Gardasil vaccination at the age of first sexual intercourse (14 years)
- ✓ Catch-up to age 23

### ➤ **HAS CT:**

- ✓ Analysed MSD data
- ✓ Reimbursement 65%

# Example: HPV recommendations Gardasil 9 men 2019 (HAS)

## ➤ Analysis

- ✓ Insufficient HPV vaccine coverage in young girls (24%) and in MSM boys (18%)
- ✓ Vaccine efficacy on pre-cancerous lesions in girls (large drop-off); efficacy on anogenital lesions in men = 89.9 %
- ✓ Vaccine efficacy on other cancers (ENT): unknown
- ✓ Vaccine safety = OK
- ✓ Medico-economic study
- ✓ Vaccination of boys =
  - leverage for vaccination of girls
  - ethics

## ➤ Public review: 194 participants

## ➤ Recommendation (final)

- ✓ Boys 11-13 years: 2 doses
- ✓ Boys 14-19 years: 3 doses
- ✓ MSM < 27 years: 3 doses

✓ CT: reimbursement 65%

# Evaluation of both vaccination recommendations and of vaccines at the HAS

## Entreprises pharmaceutiques

Demande d'inscription  
calendrier vaccinal et  
remboursement

## Auto-saisines

Veille, sujets  
transversaux...

## Ministère chargé de la santé

### Autres demandeurs

Calendrier vaccinal, saisine,  
saisine urgente, MMO

**HAS**  
HAUTE AUTORITÉ DE SANTÉ

Commission  
de la  
Transparence  
(CT)

Synthèse  
des  
données

**Avis CT**  
SMR, ASMR, ISP

Commission  
technique des  
vaccinations  
(CTV)

**Recommandation  
CTV**  
Stratégie vaccinale  
Saisines (±urgente)

Collège

Synthèse  
des  
données

Commission  
Evaluation  
économique et  
de santé  
publique  
(CEESP)

**Avis CEESP**  
Efficience  
Impact budgétaire

**UNCAM**  
Taux de  
remboursement

**Ministère de la santé**  
Inscription au remboursement  
Calendrier vaccinal

**CEPS**  
Prix



**Thank you for your attention.**

# CTV : composition

<p><b>Présidente :</b> <b>Vice-présidents :</b></p>	<p><b>Elisabeth BOUVET</b>  <b>Pierre COCHAT</b>, Président de la CT  <b>Valérie PARIS</b>, Président de la CEESP  <b>Daniel FLORET</b>, ancien Président du CTV au HCSP</p>	
<p><b>23</b> <b>membres avec voix délibérative</b></p>	<p>Dominique ABITEBOUL, conseiller médical INRS  Marc BAGUELIN, Economie de la santé  Laurent BELEC, PU-PH, microbiologie  Muriel BELIAH-NAPPEZ, Médecin de secteur du Territoire  Agathe BILLETTE DE VILLEMEUR, santé publique  Claire BOQUILLOD, carte de santé néonatalogie  Chantal CATEAU, Association Le lien  Bruno CHABANAS, Médecin service de santé univ.  Jean de VAUGELADE DU BREUILLAC, médecine générale  Olivier EPAULARD, infectiologie  Sylvie ESCOLANO, ingénieur de recherche  Patricia GARCIA MERIC, PH, pédiatrie  Valérie GARNIER, pharmacien  Agnès GAUTHERET-DEJEAN, PU-PH, microbiologie  Emmanuel GRIMPREL, PU-PH, pédiatrie  Marianick LAMBERT, membre de l'association Familles Rurales, administratrice du CISS  Jean-Daniel LELIEVRE, PU-PH, immunologie clinique  Judith MUELLER, santé publique  Claire ROUBAUD-BAUDRON, gériatre  Sydney SEBBAN, pédiatrie  Véronique TESSIER, sage-femme  Jean-Nicolas TOURNIER, infectiologie  Jeremy WARD, sociologue</p>	<p><b>9 membres avec voix consultatives</b></p> <p>Directeur de la sécurité sociale (<b>DSS</b>)  Directeur général de la santé (<b>DGS</b>)  Directeur central du service de santé des armées (<b>SSA</b>)  Directeur général de l'enseignement scolaire (<b>DGESCO</b>)  Directeur général du travail (<b>DGT</b>)  Directeur général de l'Agence nationale de sécurité du médicament et des produits de santé (<b>ANSM</b>)  Directeur général de l'Agence nationale de santé publique (<b>ANSP</b>)  Directeur de la Caisse nationale de l'assurance maladie des travailleurs salariés (<b>CNAM</b>),  Directeur de la Caisse centrale de la mutualité sociale agricole (<b>MSA</b>).</p> <p><i>ou leurs représentants</i></p>


# Children vaccine scheduler in France

	Birth	Months						Years									
		2	4	5	6	11	12	16-18	2	5	6	11	12-13	14	15	17	18
Coronavirus disease (COVID-19) <sup>1</sup>													COVID-19 <sup>4</sup>				
tuberculosis		BCG <sup>5</sup>															
diphtheria		D	D			D				D	d						
tetanus		TT	TT			TT				TT	TT						
pertussis		acP <sup>6</sup>	acP			acP				acP	acp						
poliomyelitis		IPV	IPV			IPV				IPV	IPV						
Haemophilus influenzae type b infection		Hib	Hib			Hib											
hepatitis B	HepB <sup>7</sup>	HepB	HepB			HepB		HepB <sup>8</sup>									
pneumococcal disease <sup>2</sup>		PCV	PCV			PCV		PCV13+PPSV23 <sup>9</sup>									
meningococcal disease <sup>3</sup>				MenC			MenC	MenC <sup>10</sup>									
measles					MEAS <sup>11</sup>	MEAS	MEAS			MEAS <sup>12</sup>					MEAS <sup>13</sup>		
mumps						MUMPS	MUMPS			MUMPS <sup>12</sup>					MUMPS <sup>13</sup>		
rubella						RUBE	RUBE			RUBE <sup>12</sup>					RUBE <sup>14</sup>		
human papillomavirus infection											HPV (F/M) <sup>15</sup>		HPV (F) <sup>16</sup>				



# RECOVAC (new strategy)

## ➤ Steps



# AVIVAC (integration into an existing strategy)

## ➤ Situations

- Availability of a new vaccine that can be integrated into an existing defining strategy
- Extension of indication or a major modification to marketing autorisation that doesn't change a defined strategy

## ➤ Principal steps

